Among 19 of the 22 patients with recurrent GBM who received four doses, 58% showed increased response of chemokines, including interferon gamma (IFN-γ), interferon alfa (IFN-α), and CXCL10, leading to sustained immune responses and prolonged patient survival. This evidence concerns the gene CXCL10 and glioblastoma.